Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (24 quarters reported)
$172M in Q4 2020 → $854M now. Hover for any quarter.
As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Kodiak Sciences Inc | 8.3% | Added 37% | 750,170 | $71.1M |
| Celcuity Inc | 7.5% | Added 60% | 803,193 | $63.9M |
| Cogent Biosciences Inc | 5.9% | Added 23% | 1,574,698 | $50.4M |
| Urogen Pharma Ltd | 5.5% | Trimmed 12% | 1,148,689 | $46.7M |
| Immunome Inc | 5.3% | Added 3.8% | 2,092,715 | $45M |
| Monte Rosa Therapeutics Inc | 4.3% | Added 181% | 3,112,773 | $37.1M |
| Sagimet Biosciences Inc | 4.3% | Added 28% | 3,745,990 | $37M |
| Ascendis Pharma A/s | 4.1% | Trimmed 26% | 152,175 | $34.7M |
| Rhythm Pharmaceuticals Inc | 3.9% | Added 12% | 348,317 | $33.2M |
| Biogen Inc | 3.0% | Added 134% | 112,790 | $25.5M |
| Immunovant Inc | 2.5% | Added 0.8% | 624,055 | $21.1M |
| Dianthus Therapeutics Inc | 2.4% | Trimmed 39% | 236,582 | $20.8M |
| Oruka Therapeutics Inc | 2.4% | Trimmed 30% | 247,918 | $20.6M |
| Erasca Inc | 2.3% | Added 5.3% | 1,330,455 | $19.5M |
| AS Abivax Sa | 2.0% | Added 3.6% | 175,699 | $17.4M |
| CT Celldex Therapeutics Inc New | 1.8% | New | 487,589 | $15.8M |
| Ovid Therapeutics Inc | 1.7% | Added 92% | 5,950,000 | $14.8M |
| Spyre Therapeutics Inc | 1.6% | Added 152% | 151,151 | $13.5M |
| Definium Therapeutics Inc | 1.5% | Trimmed 14% | 345,946 | $13.2M |
| Helix Acquisition Corp Iii | 1.5% | Added 2.6% | 1,208,030 | $12.8M |
| Alkermes PLC | 1.4% | Added 165% | 300,427 | $12.2M |
| CT Celldex Therapeutics Inc New Call | 1.4% | New | 370,700 | $12M |
| C4 Therapeutics Inc | 1.3% | Added 14% | 3,454,647 | $11.5M |
| AP Avalyn Pharmaceuticals Inc | 1.3% | Added 14% | 378,352 | $10.8M |
| Oric Pharmaceuticals Inc Call | 1.1% | Added 2.9% | 702,400 | $9.46M |
| Cerus Corp | 1.1% | Added 14% | 3,950,595 | $9.4M |
| AO Alx Oncology Hldgs Inc | 1.1% | Added 14% | 6,565,960 | $9.13M |
| Zenas Biopharma Inc | 1.1% | Trimmed 34% | 334,057 | $9.01M |
| Compass Pathways PLC | 1.0% | Added 43% | 717,356 | $8.92M |
| RA Rainier Acquisition Corp | 1.0% | New | 853,875 | $8.71M |
| Compugen Ltd | 1.0% | Added 13% | 3,586,785 | $8.54M |
| Savara Inc | 0.9% | Added 12% | 1,518,833 | $7.84M |
| Vaxcyte Inc | 0.8% | Trimmed 14% | 125,080 | $7.12M |
| Yarrow Bioscience Inc | 0.8% | New | 301,919 | $6.8M |
| Ibio Inc | 0.7% | Added 52% | 5,357,088 | $6.32M |
| AT Arcturus Therapeutics Hldgs | 0.7% | New | 459,899 | $6.3M |
| Monte Rosa Therapeutics Inc Call | 0.7% | Added 75% | 525,000 | $6.26M |
| PP Praxis Precision Medicines I | 0.7% | Trimmed 70% | 19,753 | $5.75M |
| KP Kiniksa Pharmaceuticals Intl | 0.7% | New | 75,697 | $5.65M |
| Enliven Therapeutics Inc | 0.7% | Trimmed 75% | 121,452 | $5.57M |
| Solid Biosciences Inc | 0.6% | Added 14% | 760,337 | $5.5M |
| Evommune Inc | 0.6% | New | 594,027 | $4.91M |
| Syndax Pharmaceuticals Inc | 0.5% | Trimmed 80% | 247,418 | $4.65M |
| Benitec Biopharma Inc | 0.5% | Trimmed 35% | 443,109 | $4.43M |
| Research Alliance Corp Iii | 0.5% | Added 12% | 404,728 | $4.38M |
| BT Blossomhill Therapeutics Inc | 0.4% | New | 202,104 | $3.77M |
| Faeth Therapeutics Inc | 0.4% | New | 124,098 | $3.69M |
| Abeona Therapeutics Inc | 0.4% | Added 14% | 693,441 | $3.64M |
| RA Research Alliance Corp Iv | 0.4% | New | 301,962 | $3.5M |
| Adlai Nortye Group Ltd | 0.4% | New | 216,617 | $3.47M |
| Palisade Bio Inc | 0.4% | New | 2,335,602 | $3.15M |
| Disc Medicine Inc | 0.4% | Trimmed 43% | 47,312 | $3.1M |
| Absci Corporation Put | 0.3% | Added 62% | 254,700 | $2.74M |
| Tela Bio Inc | 0.3% | Unchanged | 2,137,201 | $2.46M |
| Zevra Therapeutics Inc | 0.3% | New | 200,260 | $2.2M |
| Oric Pharmaceuticals Inc | 0.3% | Trimmed 78% | 160,552 | $2.16M |
| Contineum Therapeutics Inc | 0.2% | Trimmed 46% | 158,964 | $2.13M |
| Moderna Inc | 0.2% | New | 10,000 | $1.93M |
| Elutia Inc | 0.2% | Unchanged | 2,192,980 | $1.73M |
| Fulcrum Therapeutics Inc Call | 0.2% | Unchanged | 391,900 | $1.45M |
Showing top 60 of 70 positions.
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2026 · filed November 12, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Celcuity Inc | Added | +302,197 | +$24M | 7.5% |
| Monte Rosa Therapeutics Inc | Added | +2,004,478 | +$23.9M | 4.3% |
| AE Ark ETF Tr | Exited | −500,000 | −$21M | — |
| Kodiak Sciences Inc | Added | +203,914 | +$19.3M | 8.3% |
| Veracyte Inc | Exited | −318,001 | −$18.7M | — |
| Syndax Pharmaceuticals Inc | Trimmed | −966,972 | −$18.2M | 0.5% |
| Enliven Therapeutics Inc | Trimmed | −367,930 | −$16.9M | 0.7% |
| CT Celldex Therapeutics Inc New | New | +487,589 | +$15.8M | 1.8% |
| Syndax Pharmaceuticals Inc | Exited | −693,600 | −$15.2M | — |
| Guardant Health Inc | Exited | −99,826 | −$15M | — |
Showing the 10 largest of 88 changes.
quarter ended June 30, 2026 · filed August 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR Series Trust | Exited | −825,000 | −$105M | — |
| Kalvista Pharmaceuticals Inc | Exited | −2,876,407 | −$57.9M | — |
| Ascendis Pharma A/s | New | +206,234 | +$55M | 5.7% |
| Nuvalent Inc | Exited | −354,914 | −$36.4M | — |
| Ascendis Pharma A/s | Exited | −124,658 | −$28.5M | — |
| Dianthus Therapeutics Inc | Trimmed | −264,746 | −$25.8M | 4.0% |
| Enliven Therapeutics Inc | New | +489,382 | +$24.8M | 2.6% |
| Sagimet Biosciences Inc | New | +2,927,698 | +$22.6M | 2.4% |
| Monte Rosa Therapeutics Inc | Trimmed | −893,745 | −$21.6M | 2.8% |
| AE Ark ETF Tr | New | +500,000 | +$21M | 2.2% |
Showing the 10 largest of 96 changes.
quarter ended March 31, 2026 · filed May 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR Series Trust | New | +825,000 | +$105M | 10.8% |
| Zenas Biopharma Inc | New | +1,135,935 | +$22.2M | 2.3% |
| Ascendis Pharma A/s | Added | +75,430 | +$17.3M | 2.9% |
| SR Scholar Rock Hldg Corp | New | +339,613 | +$16.7M | 1.7% |
| Alkermes PLC | New | +460,314 | +$16.3M | 1.7% |
| Monte Rosa Therapeutics Inc | Added | +972,974 | +$16M | 3.4% |
| Immunome Inc | Added | +724,068 | +$15.8M | 4.1% |
| Rhythm Pharmaceuticals Inc | Added | +170,050 | +$14.8M | 2.7% |
| AS Abivax Sa | Trimmed | −119,663 | −$13.3M | 3.4% |
| Cg Oncology Inc | Trimmed | −194,809 | −$13.2M | 1.1% |
Showing the 10 largest of 89 changes.
quarter ended December 31, 2025 · filed February 12, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Avidity Biosciences Inc | Exited | −844,633 | −$36.8M | — |
| Akero Therapeutics Inc | Exited | −643,636 | −$30.6M | — |
| Celcuity Inc | Added | +286,446 | +$28.6M | 5.2% |
| UT United Therapeutics Corp Del | Exited | −59,900 | −$25.1M | — |
| Rhythm Pharmaceuticals Inc | Trimmed | −234,046 | −$25.1M | 2.0% |
| Immunome Inc | New | +1,126,210 | +$24.2M | 3.4% |
| Insmed Inc | Trimmed | −135,392 | −$23.6M | 1.7% |
| Cidara Therapeutics Inc | Exited | −220,902 | −$21.2M | — |
| Olema Pharmaceuticals Inc | Trimmed | −727,261 | −$18.2M | 0.7% |
| UN Uniqure Nv | New | +720,800 | +$17.2M | 2.4% |
Showing the 10 largest of 101 changes.
quarter ended September 30, 2025 · filed November 12, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AS Abivax Sa | New | +539,704 | +$45.8M | 6.2% |
| Merus N V | Exited | −741,972 | −$39M | — |
| Verona Pharma PLC | Exited | −358,297 | −$33.9M | — |
| UT United Therapeutics Corp Del | New | +59,900 | +$25.1M | 3.4% |
| Dianthus Therapeutics Inc | Added | +579,160 | +$22.8M | 3.6% |
| Neurocrine Biosciences Inc | Exited | −162,969 | −$20.5M | — |
| Merus N V | Exited | −382,500 | −$20.1M | — |
| 89bio Inc | Exited | −2,037,087 | −$20M | — |
| Avidity Biosciences Inc | Added | +434,633 | +$18.9M | 5.0% |
| Soleno Therapeutics Inc | Exited | −204,591 | −$17.1M | — |
Showing the 10 largest of 98 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Merus N V | New | +382,500 | +$20.1M | 3.7% |
| Verona Pharma PLC | Trimmed | −187,575 | −$17.7M | 6.2% |
| SS SPDR Series Trust | New | +200,000 | +$16.6M | 3.1% |
| Nuvalent Inc | Trimmed | −203,435 | −$15.5M | 3.3% |
| Cg Oncology Inc | New | +541,034 | +$14.1M | 2.6% |
| SR Scholar Rock Hldg Corp | New | +341,010 | +$12.1M | 2.2% |
| Disc Medicine Inc | Exited | −236,471 | −$11.7M | — |
| Neurocrine Biosciences Inc | Added | +90,386 | +$11.4M | 3.8% |
| Vaxcyte Inc | New | +287,796 | +$9.36M | 1.7% |
| Urogen Pharma Ltd | Added | +641,324 | +$8.79M | 5.1% |
Showing the 10 largest of 85 changes.
quarter ended March 31, 2025 · filed May 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Pliant Therapeutics Inc | Exited | −1,315,601 | −$17.3M | — |
| IT Intra-cellular Therapies Inc | Exited | −179,085 | −$15M | — |
| Kalvista Pharmaceuticals Inc | Added | +1,086,811 | +$12.5M | 4.0% |
| Soleno Therapeutics Inc | New | +166,417 | +$11.9M | 2.4% |
| 89bio Inc | Added | +1,413,987 | +$10.3M | 2.2% |
| Poseida Therapeutics Inc | Exited | −1,012,307 | −$9.72M | — |
| Neurocrine Biosciences Inc | New | +72,583 | +$8.03M | 1.6% |
| SR Scholar Rock Hldg Corp | Exited | −183,243 | −$7.92M | — |
| Cogent Biosciences Inc | Exited | −921,137 | −$7.18M | — |
| Disc Medicine Inc | Added | +126,090 | +$6.26M | 2.4% |
Showing the 10 largest of 83 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Poseida Therapeutics Inc | Trimmed | −2,675,241 | −$25.7M | 2.1% |
| Pliant Therapeutics Inc | New | +1,315,601 | +$17.3M | 3.8% |
| Syndax Pharmaceuticals Inc | Added | +851,654 | +$11.3M | 3.6% |
| Alnylam Pharmaceuticals Inc | Exited | −35,774 | −$9.84M | — |
| SR Scholar Rock Hldg Corp | New | +183,243 | +$7.92M | 1.7% |
| Verona Pharma PLC | Added | +167,148 | +$7.76M | 5.2% |
| Protagonist Therapeutics Inc | Exited | −146,657 | −$6.6M | — |
| Ascendis Pharma A/s | Added | +46,491 | +$6.4M | 1.6% |
| Sarepta Therapeutics Inc | Exited | −51,245 | −$6.4M | — |
| Akero Therapeutics Inc | New | +220,000 | +$6.12M | 1.3% |
Showing the 10 largest of 83 changes.
Loading...